Efficacy and Safety of the Fixed-dose Combination Atorvastatin/Fenofibrate vs Atorvastatin in Patients With T2D and DLP.

Inclusion Criteria: * That the subject agrees to participate in the study and gives their informed consent in writing. * Both genres. * Age 18 to 75 years old. * Diagnosis of type 2 diabetes mellitus with adequate glycemic control defined by HbA1c ≤ 7.5% at the time of selection. * Diagnosis of dyslipidemia prior to the start of the study (LDL cholesterol\> 100 mg / dl and triglycerides\> 150 mg / dl). * Willing to avoid sexual contact or to use a barrier method of contraception while conducting the study. Exclusion Criteria: * The drug is contraindicated for medical reasons. * Consumption of oral contraceptives, cyclosporine or strong cytochrome p450 (CYP) 3A4 inhibitors, protease inhibitors, erythromycin and azoles. * Patients with Type 1 Diabetes Mellitus. * Acute or Severe renal dysfunction (glomerular filtration \<30 ml / min / 1.72 m2). * History of chronic liver disease or ALT and / or AST ≥ 2 times the upper limit of normal, or GGT ≥3 times the upper limit of normal. * Chronic or acute pancreatitis except for acute pancreatitis due to severe hypertriglyceridemia (defined by the presence of triglycerides\> 1000 mg / dl and / or milky plasma, in the absence of other etiological factors of pancreatitis). * Patients with active gallbladder disease (defined as acute or chronic gallbladder disorders associated with clinical signs or symptoms). * Patient with a history or presence of myopathies. * Pregnant or lactating women. * Known contraindication or hypersensitivity t…